Glucagon-Like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

GLA may help with hair loss due to its anti-inflammatory properties and 5ar enzyme inhibition. It's considered potentially more important than biotin, especially for those already using finasteride and dutasteride.

A new drug targeting prolactin is being discussed for hair regrowth, but skepticism remains as many still rely on minoxidil and finasteride. Concerns include the drug's effectiveness compared to existing treatments and whether it works for those already using 5AR inhibitors.

Novo is exploring hair loss treatments, possibly linked to GLP-1 drugs like Ozempic, which may contribute to hair loss. Some users are skeptical about new treatments, suggesting existing drugs like finasteride and minoxidil are being rebranded.

Rubedo Life Sciences is developing a GPX4 modulator, RLS-1496, for hair loss treatment, showing promising hair follicle growth in early tests. Concerns include potential side effects like organ damage, with a realistic market release several years away.